License & Other Revenue was X4 Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $28.59M of $35.11M (81%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| License & Other Revenue | — | $28.59M |
| Product Revenue, Net | $2.56M | $6.52M |
| Total | $2.56M | $35.11M |
X4 Pharmaceuticals brought in $35.11M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. X4 Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $2.56M. License & Other Revenue was the largest at $28.59M (81.4%), ahead of Product Revenue, Net at $6.52M (18.6%).
X4 Pharmaceuticals began breaking out License & Other Revenue in fiscal 2025, when it brought in $28.59M.
United Kingdom Special Pharmacy Customer was X4 Pharmaceuticals’s largest revenue line in fiscal 2025, bringing in $28.60M of $35.10M (81%).
| Customer | FY 2024 | FY 2025 |
|---|---|---|
| United Kingdom Special Pharmacy Customer | — | $28.60M |
| U.S. Specialty Pharmacy Customer | $2.60M | $6.50M |
| Total | $2.60M | $35.10M |
X4 Pharmaceuticals brought in $35.10M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. X4 Pharmaceuticals regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $2.60M. United Kingdom Special Pharmacy Customer was the largest at $28.60M (81.5%), ahead of U.S. Specialty Pharmacy Customer at $6.50M (18.5%).
X4 Pharmaceuticals began breaking out United Kingdom Special Pharmacy Customer in fiscal 2025, when it brought in $28.60M.
X4 Pharmaceuticals (XFOR) reports its revenue by product and service and by customer. In fiscal 2025, License & Other Revenue was its largest product and service line, bringing in $28.59M (81.4% of the total), followed by Product Revenue, Net at $6.52M (18.6%).
License & Other Revenue was X4 Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $28.59M, or 81.4% of the $35.11M total across its two product and service lines.
United Kingdom Special Pharmacy Customer was X4 Pharmaceuticals' largest revenue line in fiscal 2025, bringing in $28.60M, or 81.5% of the $35.10M total across its two revenue lines.
Every figure comes from X4 Pharmaceuticals' annual financial filings, as reported. Each line keeps the name X4 Pharmaceuticals gives it, and years follow its fiscal calendar.
X4 Pharmaceuticals' revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.